RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
RBC Capital analyst Luca Issi downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Sector Perform and raises the price target from $61 to $72.
RBC Capital analyst Luca Issi downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Sector Perform and raises the price target from $61 to $72.